Avid Bioservices Inc (CDMO)

[asmarterwookie]

Bavituximab, the lead compound in Peregrine's immuno-oncology development program, blocks PS to remove this immunosuppressive signal and sends an alternate immune activating signal. PS targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in robust anti-tumor immune responses.

So we all can agree that Peregrines' PS Licensed Technology is two fold in the broadest of context...The PATENTED IP is the targeting of PS...while the Anti-Phosphatidylserine Platform(APP) is being built up that IP.

I find the qoute "resulting in ROBUST anti-tumor immune response" very interesting. Is it robust alone or in combination?

Have tighter controls on who is conducting and viewing trials shown a more robust response? What about the latency?

Time will tell what this technology can REALLY do!

Enjoy the Day!

wook